key: cord-0014986-8qx849f0 authors: Harahsheh, Ashraf S.; Dahdah, Nagib; Newburger, Jane W.; Portman, Michael A.; Tulloh, Robert; McCrindle, Brian W.; Cimaz, Rolando; Burns, Jane C. title: Reply date: 2020-06-30 journal: J Pediatr DOI: 10.1016/j.jpeds.2020.06.072 sha: f2a407dd53dcd30ec331e868e18e7505e84861f4 doc_id: 14986 cord_uid: 8qx849f0 nan To the Editor: We thank Bassareo et al for their comments and agree that our community needs to come together to improve timely diagnosis and treatment of children with Kawasaki disease and Kawasaki disease-like illnesses during the 2019 novel coronavirus disease (COVID-19) pandemic to prevent the development of coronary artery aneurysms. We would like to use this opportunity to provide context for writing our original letter and what we have learned in the interim. Between January 1, 2020, and April 1, 2020, we noted a decrease in the number of children presenting to large academic centers with Kawasaki disease. Several children at different centers presented late with Kawasaki disease; one of them was diagnosed with giant aneurysm. We were concerned that the "health care providers have focused on [the 2019 novel coronavirus disease] management during the pandemic" and that patients with Kawasaki disease were underdiagnosed or underwent delayed treatment. Our letter was submitted on April 10, 2020, revised on April 20, 2020, and accepted 1 day later. On April 26, 2020-5 days after the letter's acceptance-cases of severe inflammatory syndrome were reported in the UK with some patients having features of Kawasaki disease. 1,2 Shortly after, cases were reported first throughout Europe and then in the eastern US. 3, 4 However, we believe that the estimated 30-fold increase in Kawasaki disease is inaccurate because the investigators did not account for typical seasonal variations. 5 Multiple different case definitions have been developed so far by various societies and public health agencies in response to the rapidly emerging syndrome 1,6-9 ( Figure; available at www.jpeds.com). With the emergence of the multisystem inflammatory syndrome in children (also referred to as the pediatric multisystemic inflammatory syndrome), awareness about Kawasaki disease has increased. We should now focus not only on early treatment of classic Kawasaki disease to prevent coronary artery aneurysm but also on investigating the immunobiology and developing treatment to prevent heart disease in multisystem inflammatory syndrome in children/pediatric multisystemic inflammatory syndrome. To the Editor: I read with interest the report by Zurita-Cruz concerning the utilization of a resistin/uric acid index as a prognostic marker for body mass index (BMI) reduction. 1 It is intriguing that both uric acid alone and the resistin/ uric acid index provided significantly different values for those with vs those without BMI z-score reduction with metabolite scores of 6.3 AE 1.7 vs 5.3 AE 0.7 (P £ .001) and 2.7 AE 0.6 vs 2.2 AE 0.9 (P = .02). It has previously been noted that uric acid alone can predict weight loss in those undergoing weight loss surgery. 2 Could uric acid, as a more commonly tested (and thus less expensive) metabolite, prove just as useful as the suggested index in weight loss prediction within this tested cohort? It would be of interest to know how the composite indices were formed. It is surprising that the leptin/uric acid index performs so poorly when one would suspect an additive or multiplicative composite index to maintain a higher score (even if not significant) in those with a BMI z-score reduction than those without. Comorbidities associated with obesity were recorded, but were not reported or included as controlled covariates within the analysis. Knowing these may provide interesting insights to ensure that confounding aspects of a metabolic syndrome are not contributory to the results. Finally, it is increasingly recognised that BMI may not be the most accurate method for determining adiposity Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study Hyperinflammatory shock in children during COVID-19 pandemic Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 Hyperinflammatory shock in children during COVID-19 pandemic Severe COVID-19 in children and young adults in the Washington, DC Metropolitan Region An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study Multisystem inflammatory syndrome in children and adolescents with COVID-19 Pediatric multi-system inflammatory syndrome temporally associated with CVOID-19 Interim case definition in New York state Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children -15 Timeline of Kawasaki disease through the 2019 noval coronavirus disease (COVID-2019) pandemic College of Paediatrics and Child Health; UK, United Kindom; WHO, World Health Organization